These observations corroborate our earlier studies, which showed a significant reduction in several microglial activation markers accompanied by a profound decrease in amyloid plaques when the Tg2576 mouse model of AD was treated with a C5aR1 antagonist. The gene discussed is C5AR1; the disease is Alzheimer disease.